Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23923262 | 1.00 | PDE4A (0.36) | PDE4AALDH1A1TSHRCYP2C9 | |
| SCHEMBL1037497 | 1.00 | PDE4A (0.36) | PDE4AALDH1A1TSHRCYP2C9 | |
| SCHEMBL19384838 | 0.84 | PDE4A (0.39) | PDE4AALDH1A1TSHRCYP2C9 | |
| SCHEMBL20853846 | 0.83 | TSHR (0.32) | TSHR | |
| SCHEMBL5029667 | 0.82 | PDE4A (0.38) | PDE4AALDH1A1TSHRCYP2C9 | |
| SCHEMBL570514 | 0.80 | TSHR (0.41) | TSHR | |
| SCHEMBL645759 | 0.80 | PDE4A (0.39) | PDE4AALDH1A1TSHRCYP2C9 | |
| SCHEMBL7770754 | 0.80 | TSHR (0.41) | TSHR | |
| SCHEMBL27671066 | 0.80 | TSHR (0.41) | TSHR | |
| SCHEMBL570513 | 0.80 | TSHR (0.41) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111386128-A | Combination therapy for immunomodulation | 奥瑞基尼探索技术有限公司 | 2020-07-07 | — | — | CN | claimed |
| US-5808111-A | Stable acitretinoid compounds | THE OHIO STATE RESEARCH FOUNDATION (US) | 1998-09-15 | — | — | US | claimed |
| EP-4282853-A1 | PROCESS FOR THE PREPARATION OF MESACONIC ACID ESTERS | Symrise AG (DE) | 2023-11-29 | — | — | EP | disclosed |
| US-20220395521-A1 | MICROBIOME REGULATORS AND RELATED USES THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2022-12-15 | — | — | US | disclosed |
| CN-110099990-B | Perfume mixture | 西姆莱斯股份公司 | 2022-11-29 | — | — | CN | disclosed |
| CN-115322833-A | Perfume mixture | 西姆莱斯股份公司 | 2022-11-11 | — | — | CN | disclosed |
| US-10988434-B2 | Fragrance mixture | SYMRISE AG (DE) | 2021-04-27 | — | — | US | disclosed |
| CN-111386128-A | Combination therapy for immunomodulation | 奥瑞基尼探索技术有限公司 | 2020-07-07 | — | — | CN | disclosed |
| CN-111372584-A | Dual inhibitors of the TIM-3 and PD-1 pathways | 奥瑞基尼探索技术有限公司 | 2020-07-03 | — | — | CN | disclosed |
| EP-3559179-A1 | FRAGRANCE MIXTURE | Symrise AG (DE) | 2019-10-30 | — | — | EP | disclosed |
| US-20180296582-A1 | MICROBIOME REGULATORS AND RELATED USES THEREOF | HERCULES CAPITAL, INC. | 2018-10-18 | — | — | US | disclosed |
| US-20150225758-A1 | GENETICALLY MODIFIED CELLS AND METHODS FOR MAKING ACTIVATED SUGAR-NUCLEOTIDES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-08-13 | — | — | US | disclosed |
| US-8404650-B2 | Methods of treating cancer with doxazolidine and prodrugs thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2013-03-26 | — | — | US | disclosed |
| US-20110135618-A1 | METHODS OF TREATING CANCER WITH DOXAZOLIDINE AND PRODRUGS THEREOF | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2011-06-09 | — | — | US | disclosed |
| WO-2007102888-A2 | METHODS OF TREATING CANCER WITH DOXAZOLIDINE AND PRODRUGS THEREOF | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2000001682-A1 | WATER-SOLUBLE DERIVATIVES OF PACLITAXEL, METHOD FOR PRODUCING SAME AND USES THEREOF | BCM DEVELOPPEMENT INC. (CA) | 2000-01-13 | — | — | WO | disclosed |
| EP-0207202-A1 | Anti-tumor platinum complexes | Kidani, Yoshinori (JP) | 1987-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988434-B2 | Fragrance mixture | MEP1B, ACMSD, TRPA1 | PDE4A 2359/4885ALDH1A1 631/4885TSHR 3395/4885 |
| US-20110135618-A1 | METHODS OF TREATING CANCER WITH DOXAZOLIDINE AND PRODRUGS THEREOF | DNPEP, PEPD, PREP | PDE4A 149/4885ALDH1A1 427/4885TSHR 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.